冠心通脉胶囊对冠心病心绞痛患者白细胞介素6和肿瘤坏死因子α的影响  

Effects of Guanxin Tongmai capsule on IL-6 and TNF-α in patients with CHD

作　　者：吴勇宏[1] 雷健[2] 柯于鹤[2] 陈烈[3] 

机构地区：[1]六安市中医院,安徽六安237006 [2]武汉市第一医院,湖北武汉430022 [3]湖北中医药大学,湖北武汉430065

出　　处：《中医临床研究》2014年第4期12-13,共2页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察冠心通脉胶囊对冠心病(CHD)心绞痛患者血清白细胞介素6(IL-6)和肿瘤坏死因子α(TNF-α)含量的影响,以初步探讨冠心通脉胶囊治疗冠心病心绞痛的炎症机制。方法:将60例冠心病心绞痛患者分为治疗组和对照组,两组均连服4周为1个疗程。治疗1个疗程后对比分析两组临床疗效以及服药前后血清白细胞介素6和肿瘤坏死因子α含量。结果:治疗组总有效率85.7%,对照组总有效率90.0%,两组间临床疗效无显著性差异(P>0.05)。结论:冠心通脉胶囊能明显降低冠心病心绞痛患者血清中IL-6和TNF-α的含量,在治疗冠心病心绞痛疗效上与通心络胶囊相当,其作用可能与抗炎症反应有关。Objective： To observe the effects of Guanxin Tongmai capsule on serum Interleukin 6 （IL-6） and Tumor Necrosis Factor-α（TNF-α） in patients with angina pectoris of CHD. Methods： 60 cases were divided randomly into treated group and control group. Before and 4 weeks after treatment, the effect were to be compared between the two groups, and serum IL-6 and TNF-α content were measured with ELISA. Results： Treated group total effectiveness 85.7%, the comparison group total effectiveness 90%. There was no significant difference （P〉0.05） between the two groups in the aspect of clinical effect. Conclusion： Guanxin Tongmai capsule could decrease serum decrease serum IL-6 and TNF-αcontent in patients with angina pectoris of CHD.

关 键 词：冠心通脉胶囊 冠心病 心绞痛 白细胞介素6 肿瘤坏死因 

分 类 号：R541.4[医药卫生—心血管疾病]